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Abstract
Drug-induced liver injury (DILI) is the most
common cause of acute liver failure and a fre-
quent reason for withdrawal of candidate drugs
during preclinical and clinical testing. An im-
portant type of DILI is cholestatic liver injury,
caused by buildup of bile salts within hepato-
cytes; it is frequently associated with inhibition
of bile salt transporters, such as the bile salt
export pump (BSEP). Reliable in silico models
to predict BSEP inhibition directly from chem-
ical structures would significantly reduce costs
during drug discovery and could help avoid in-
jury to patients. Unfortunately, models pub-
lished to date have been insufficiently accurate
to encourage wide adoption. We report our de-
velopment of classification and regression mod-
els for BSEP inhibition with substantially im-
proved performance over previously published
models. Our model development leveraged the
ATOM Modeling PipeLine (AMPL) developed
by the ATOM Consortium, which enabled us
to train and evaluate thousands of candidate
models. In the course of model development,
we assessed a variety of schemes for chemical
featurization, dataset partitioning and class la-
beling, and identified those producing models
that generalized best to novel chemical entities.
Our best performing classification model was a
neural network with ROC AUC = 0.88 on our
internal test dataset and 0.89 on an indepen-
dent external compound set. Our best regres-
sion model, the first ever reported for predicting
BSEP IC50s, yielded a test set R2 = 0.56 and
mean absolute error 0.37, corresponding to a
mean 2.3-fold error in predicted IC50s, compa-
rable to experimental variation. These models
will thus be useful as inputs to mechanistic pre-
dictions of DILI and as part of computational
pipelines for drug discovery.
Introduction
Drug induced liver injury (DILI) has been re-
ported to be the leading cause of acute liver fail-
ure in the US.1 Incidence of DILI frequently re-
sults in early termination of preclinical develop-
ment and clinical trials for candidate drugs, and
imposition of black-box warnings or outright
withdrawal of marketed drugs.2,3 There are two
main forms of DILI: the more severe hepa-
tocellular form, associated with elevated ala-
nine transferase; and the less severe cholestatic
form, characterized by elevated alkaline phos-
phatase.4 Drugs can cause DILI via several dif-
ferent and overlapping mechanisms. In spite
of considerable efforts, the complex, multifacto-
rial nature of DILI renders its mechanistic un-
derstanding and prediction difficult. The most
common mechanisms covered by in vitro assays
include formation of reactive metabolites; in-
hibition of transporters involved in the export
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of bile acids from hepatocytes; mitochondrial
toxicity; and other cellular toxicity pathways.
One likely contributor to DILI is inhibition of
the bile salt export pump (BSEP) transporter,
leading to increase of intracellular bile salt con-
centrations to toxic levels.5–7
BSEP, encoded by the gene ABCB11, belongs
to a family of ATP-binding cassette (ABC)
transporters that also includes P-glycoprotein
(ABCB1) and the multidrug resistance proteins
MRP2 (ABCC2), MRP3 (ABCC3) and MRP4
(ABCC4). These transporters mediate the ex-
cretion of individual bile constituents from hep-
atocytes into canaliculi or blood vessels and
play key roles in bile formation and cholestasis.
BSEP, mainly expressed in the liver, is localized
in the cholesterol-rich canalicular membrane
of hepatocytes with twelve transmembrane-
spanning domains. Its function is to export un-
conjugated and conjugated bile acids and salts
from hepatocytes into the bile, and to thereby
maintain a low intracellular concentration of
bile salts. Particularly in humans, impairment
of BSEP function can lead to disturbed bile salt
excretion and to cholestasis.
Inhibition of BSEP has been clearly linked
to cholestatic liver injury in several studies.5,8
While several transporters may be involved
in cholestasis, drug-like compounds are more
likely to inhibit BSEP than the other trans-
porters. In a recent study of 635 currently and
formerly marketed drugs,9 148 (23%) inhibited
BSEP function with IC50s less than 100 µM,
and 78 (12%) with IC50s less than 25 µM. By
contrast, only 4% and 7% of compounds tested
had IC50s less than 100 µM for MRP2 and
MRP3, respectively. MRP4 inhibition was less
common than BSEP inhibition but more com-
mon than MRP2 and MRP3, with 17% of com-
pounds measured having IC50s below 100 µM
and 9% with IC50s less than 25 µM.
While in vitro assays for BSEP inhibition can
be performed with moderately high through-
put, they are currently too expensive to ap-
ply routinely to screen hundreds or thousands
of candidate drugs, and the cost of synthesiz-
ing lead compounds precludes the use of these
assays in the earliest stages of drug discovery.
Therefore, in silico approaches to identify com-
pounds as potential BSEP inhibitors would be
much more cost effective.
Some groups have addressed the need for
computational prediction of BSEP inhibition
through mechanistic approaches, such as dock-
ing and molecular dynamics simulations.10 Un-
fortunately, accurate mechanistic models of
protein-ligand interactions require high resolu-
tion protein structures, which are not currently
available for BSEP. While approximate struc-
tures have been constructed based on the ho-
mology of BSEP and P-glycoprotein, the pre-
dictive accuracies of models based on these
structures lag behind the accuracy of ligand-
based models. In addition, such models are
complicated by the difficulty of simulating in-
teractions with the surrounding cell membrane.
As a result, efforts to predict BSEP inhibition
have focused on machine learning approaches,
based on structural features of small molecule
ligands. One of the earliest published models11
was a multiple linear regression model, which
fit single-concentration percent inhibition val-
ues to a linear combination of “chemical frag-
mentation codes” (occurrence counts of partic-
ular structural motifs). The authors fit the
model to data for 38 drugs and reported a coef-
ficient of determination (R2) of 0.952 across the
training dataset. The authors did not perform
any cross-validation to determine how well their
model generalizes to compounds outside their
training set.
Warner et al.12 built several classification
models based on descriptor features calculated
by AstraZeneca in-house software for 624 com-
pounds, assigned randomly to training (70%)
and test sets (30%). Compounds were cate-
gorized as BSEP inhibitors if their IC50s were
below 300 µM. Their best model was a sup-
port vector machine which yielded 87% accu-
racy, precision 0.85 and recall 0.90. While their
model depends on in-house descriptor calcula-
tions and was not published, their dataset was
published as supporting information.
Pedersen et al.13 developed partial least-
squares (PLS) classification models using de-
scriptors calculated by a combination of in-
house and commercial software (Dragon 6, AD-
METPredictor). Their dataset consisted of 249
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compounds, randomly split into training (65%)
and test sets (35%). Compounds were classified
based on their percent inhibition of BSEP func-
tion at 50 µM concentration: as weak inhibitors
if they reduced taurocholic acid (TA) transport
to between 50% and 72.5% of control values,
and as strong inhibitors if they reduced it to
50% or less. The PLS model for discriminat-
ing strong inhibitors from non-inhibitors uses a
combination of 15 descriptors; the authors re-
port 89% accuracy on the test set, with preci-
sion 0.84 and recall 0.76. Weak inhibitors were
excluded from the test set for this model. A
model for discriminating all inhibitors (strong
and weak) from non-inhibitors performed less
well, with 73% accuracy, precision 0.65 and re-
call 0.63. The models are not publicly available,
but the dataset is included within the article.
Montanari et al.14 built a random forest
model using IC50 data for 838 compounds
contributed by AstraZeneca to the IMI eTox
project (http://etoxproject.eu). The fea-
ture set consisted of 78 descriptors calculated
by the commercial software MOE.15 Accord-
ing to the authors, the descriptors were chosen
based on interpretability, rather than informa-
tion content or correlation with BSEP inhibi-
tion. Compounds were labeled as inhibitors if
the IC50 was less than or equal to 10 µM, and
as noninhibitors if the IC50 was greater than
50 µM. Notably, weak inhibitors with IC50s
between 10 and 50 µM were excluded from
the training and testing datasets. Compounds
were assigned randomly to training (80%) and
test sets (20%). In addition, the authors com-
piled an external validation dataset of 156 com-
pounds, taken from the Hirano et al. study
and from a dataset published by Morgan et al.8
The IC50 thresholds used to label compounds
as inhibitors or non-inhibitors in the external
datasets differed somewhat from those used for
the training and testing data, apparently due
to differences in the assays used to generate the
data. To select the best number of trees for
random forest models, the authors used 5-fold
and 10-fold cross-validation. The best model
yielded 80% accuracy on the test set, with pre-
cision 0.70 and recall 0.67. On the external test
set, accuracy was 88%, with precision 0.77 and
recall 0.77. To our knowledge, Montanari et al.
were the first to publish their model; it is avail-
able as a KNIME workflow that requires the
user to have a license for MOE to compute the
necessary descriptors.
Although the published models show promis-
ing performance when tested on existing phar-
maceutical compounds, it remains uncertain
how well these models generalize to compounds
with novel chemistry. One area of concern is
the method used to partition compounds into
training and test sets. All three of the classifica-
tion models discussed above were trained using
random splitting to select a test set. As pointed
out by Rohrer,16 Wallach17 and others, random
selection leads to biased test sets in which many
test compounds are structurally similar to com-
pounds in the training set. Model selection
based on performance on such test sets tends
to favor models that “memorize” the training
data, rather than those which learn to gener-
alize over common chemical features. Several
dataset splitting strategies have been proposed
to improve model generalizability,17–19 but have
yet to be employed to train predictive models
of BSEP inhibition.
Another concern is the use of dual IC50 or
percent inhibition thresholds to classify com-
pounds as BSEP inhibitors or non-inhibitors.14
Excluding weak inhibitors from the training
and testing datasets simplifies the classification
task, by removing compounds with intermedi-
ate IC50 values that are inherently most dif-
ficult to classify. When applied in a realis-
tic drug discovery context, however, the model
will have to predict inhibition for compounds
whose true IC50s may fall in the intermedi-
ate range. Therefore, performance metrics re-
ported for test sets with weak inhibitors ex-
cluded are likely to be inflated relative to what
can be expected in a realistic drug discovery
scenario.
Except for the model reported by Hirano et
al.,11 which predicts percent inhibition of BSEP
function at a fixed concentration, we are un-
aware of any published regression models for
BSEP inhibition. Models that can predict an
IC50 or the percent inhibition at a specified
concentration are needed to provide input to
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quantitative systems models for hepatotoxicity
such as DILIsym20 and to computational drug
design frameworks. However, regression models
are difficult to fit to IC50 data because many
data values are censored (e.g., the IC50 is re-
ported as “greater than 100 µM” if the com-
pound was tested at a maximum concentration
of 100 µM, and the transporter activity was not
at least 50% reduced at that concentration).
Our hypothesis for the research reported here
was that, by applying rigorous machine learn-
ing techniques and extensive hyperparameter
searches, one could create a set of predictive
models for BSEP inhibition that would better
generalize to molecules with novel chemistry.
We describe here the process we devised to train
and evaluate models in order to avoid the short-
comings of previous work. In particular, we will
show that the method used for splitting data
into training, validation and test sets has a large
effect on measured performance and general-
ization power. We compare the performance
of different types of models (i.e., neural net-
works and random forests) using different fea-
ture sets (ECFP fingerprints and chemical de-
scriptors). We also demonstrate the inflation of
performance metrics resulting from use of dual-
threshold classification schemes and show how
a single threshold leads to more realistic esti-
mates of performance on novel compounds. We
present results from training both classification
and regression models, going beyond previous
work that addressed the classification problem
only.
Our research serves as an application case
study for the open source ATOM Modeling
PipeLine (AMPL),21 developed by our team at
the Accelerating Therapeutics for Opportuni-
ties in Medicine (ATOM) Consortium. In or-
der to facilitate reproduction of our research,
we have released example models for BSEP
inhibition based on open data and descrip-
tor calculations, which are available on the
AMPL GitHub repository (https://github.
com/ATOMconsortium/AMPL). We discuss the
performance of these models and compare them
to models trained using mixed open and propri-
etary data.
Methods
Data curation
We constructed a combined training and testing
data set using data from two sources: A pro-
prietary BSEP assay data set donated to the
ATOM Consortium by GSK, containing data
from 601 compounds; and a published data
set included as supplemental data by Morgan
et al.,9 containing data for 634 compounds.
Both data sets were based on measurements
of [3H]-taurocholate transport in inverted mem-
brane vesicles, following similar protocols. For
the Morgan et al. data set, we used the
ChEMBL 25 database22 to map the published
compound names to ChEMBL compound IDs
and SMILES strings; we found unambiguous
matches for 631 compounds. For both data
sets, we used the RDKit23 and MolVS24 Python
packages to standardize SMILES strings and
remove salts. We excluded organometallic
compounds, compounds with molecular weight
greater than 2000 or less than 100, and mix-
tures of molecular species (e.g. aminophylline)
from both data sets. For modeling and analy-
sis, IC50 values were converted to pIC50 values,
where pIC50 = − log10(IC50) when IC50 is ex-
pressed as molar concentration.
The resulting data sets shared 75 compound
structures in common. We compared the mea-
sured pIC50 values for these compounds be-
tween the two data sets, as shown in Figure
1. Although the GSK assay tended to report
larger pIC50 values for compounds with mea-
surable BSEP inhibition, the two assays usu-
ally agreed as to whether compounds should
be categorized as inhibitors or non-inhibitors.
We chose a threshold pIC50 = 4, correspond-
ing to an IC50 of 100 µM, based on the max-
imum concentrations tested for the two data
sets (100 or 200 µM for the GSK data, and
133 µM for the Morgan et al. data set); com-
pounds with reported pIC50 > 4 were catego-
rized as inhibitors. For the GSK data, where
most compounds had replicate measurements,
compounds were categorized as inhibitors if a
strict majority of pIC50 values were greater
than 4. Based on these criteria, the reported
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values from GSK and Morgan et al. produced
the same categorization for 62 out of 75 com-
pounds. Nine compounds were classified as in-
hibitors according to the Morgan et al. data
but not the GSK data; while four compounds
were inhibitors according to the GSK data but
not the Morgan et al. data. In all but one of
the compounds where the data sets disagreed,
the average reported pIC50 for the data set des-
ignating the compound as an inhibitor was be-
tween 4 and 5, suggesting that these were bor-
derline cases.
We concluded that the assay data from the
two data sets were sufficiently comparable to
justify combining them into one classification
data set. To combine the data sets, we used
a maximum likelihood procedure to estimate a
mean pIC50 over replicate measurements, while
taking censoring into account; when a com-
pound was in both the GSK and Morgan et al.
data sets, we treated the value from Morgan et
al. as an additional replicate. Details about
the estimation procedure are given in the sup-
plemental information.
To compare model performance against the
results of Montanari et al., we also constructed
a dual-threshold training and testing data set
from which compounds with IC50s between 10
and 50 µM (pIC50s between 4.3 and 5.0) were
excluded. In this dataset, compounds were clas-
sified as inhibitors if their IC50 was less than 10
and as non-inhibitors if IC50 was greater than
50 µM.
To provide further assessment of model per-
formance and generalization power, we com-
piled an external test data set from the data
published by Warner et al.12 We used Adobe
Acrobat DC to convert the PDF table to an
Excel spreadsheet, manually edited the spread-
sheet to align rows and columns consistently
and used an in-house Python script to remove
embedded newlines and blanks in SMILES
strings and compound names. SMILES strings
were canonicalized and salt groups removed as
for our training dataset. We identified 142
compounds appearing both in the Warner et
al. dataset and our combined training/testing
dataset and used these to assess the comparabil-
ity of IC50 measurements between the two. We
found that IC50 measurements in the Warner
et al. dataset tended to be smaller than corre-
sponding measurements in our internal dataset,
probably due to differences in assay protocols.
Therefore, to create our external classification
dataset, we used a lower IC50 threshold to label
compounds as inhibitors. We chose the thresh-
old by computing Cohen’s kappa statistic be-
tween our classifications and a set of trial clas-
sifications based on thresholds ranging from 15
to 130 and selecting the threshold that max-
imized kappa. The optimal threshold was 50
µM, which yielded a kappa value of 0.62. We
constructed the external classification dataset
using the remaining data, filtered to exclude
compounds having Tanimoto similarity greater
than 0.6 to any compound in our internal train-
ing and testing set (based on ECFP4 finger-
prints calculated by RDKit). We also excluded
compounds containing metals or with molecu-
lar weight less than 100. The final dataset con-
tained classification data for 366 compounds.
We did not create an external regression test
set, due to the limited overlap between the IC50
ranges in our dataset (1 nM – 133 µM) and that
of Warner et al. (10 – 1000 µM).
To generate the open-data classification
model released with this paper, we prepared an
additional training dataset by selecting records
from the datasets published by Morgan et al.
and Warner et al. For compounds present in
both datasets, we selected the data from the
Morgan et al. set, because the IC50 mea-
surements in that set covered a wider range.
As before, we labeled compounds as BSEP
inhibitors if their IC50 was below 50 µM,
for compounds derived from the Warner et
al. dataset, or 100 µM, for compounds from
the Morgan et al. dataset. The combined
set of compounds contained a much smaller
percentage of inhibitors (24%) than the com-
bined Morgan/GSK dataset (44%). To im-
prove the performance of open-data models,
we created a class-balanced dataset contain-
ing all the inhibitors plus a random sample of
non-inhibitors, totaling 660 compounds, 45%
of which were inhibitors. For external valida-
tion of open-data models, we used a subset of
GSK compounds filtered to exclude those with
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Tanimoto similarity greater than 0.6 to any
compound in the training set.
Featurization
SMILES strings from the combined dataset
were mapped to model input features using
three different featurization schemes. Chemi-
cal descriptors were computed using MOE us-
ing both 2D and 3D structures. We noted that
many MOE descriptors were strongly correlated
with each other due to the fact that they scaled
with molecular size, as measured by the total
number of atoms a count. To remove this de-
pendency, we replaced all descriptors d having
Pearson correlation r(d, a count) > 0.5 with
scaled versions, computed as d/a count. The
resulting set of features was pruned further to
eliminate descriptors that duplicated or were
linear functions of other descriptors or had con-
stant values.
An alternative set of chemical descriptors was
computed using the open source package “Mor-
dred”.25 The complete set of 2D and 3D de-
scriptors was pruned to exclude those that were
undefined or noncomputable for the majority of
compounds in the ATOM database. No scal-
ing or other transformations were applied to
Mordred descriptors. The resulting feature set
contained 1,555 descriptors. For the open-data
model released with this paper, Mordred de-
scriptors were used exclusively, in order to make
the model usable without the need for commer-
cial software.
Finally, extended connectivity fingerprint
(ECFP4) bit vectors with length 1024 were
computed using RDKit.
Dataset partitioning
The combined proprietary (GSK) and public
(Morgan et al.) dataset was partitioned into
training, validation and test sets containing
70%, 15% and 15% of the compounds respec-
tively. Three different partitioning strategies
were compared: random assignment, the “scaf-
fold” splitter implemented in the DeepChem
package,19 and a modified version of the asym-
metric validation embedding (AVE) debiasing
Figure 1: Measured pIC50 values for com-
pounds appearing in both the Morgan et al.
(red points) and GSK (blue) data sets. Com-
pounds with replicate uncensored values in
the GSK data set are represented by box
plots showing the interquartile range of repli-
cate measurements. Triangles represent left-
censored pIC50 values, corresponding to the
maximum concentrations tested (133 µM in the
Morgan et al. data set, 100 or 200 µM in the
GSK data set).
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splitter described by Wallach et al.17 The scaf-
fold splitter aims to increase chemical dissimi-
larity between the training, validation and test
sets by mapping compound structures to their
Bemis-Murcko scaffolds and assigning com-
pounds with the same scaffold to the same par-
titions, so that test compounds do not share
scaffolds with training compounds.
The AVE debiasing splitter aims to produce
a split that provides an improved estimate of
generalization performance. It uses a genetic al-
gorithm to optimally partition compounds into
training and test sets in order to minimize a
quantity called the AVE bias. Partitions with
large AVE bias favor models that memorize the
training data, such as k-nearest neighbor mod-
els; conversely, minimizing this bias should re-
ward models that generalize beyond the train-
ing data. The AVE bias is the sum of two
components: one that measures the likelihood
that an inhibitor in the test set is most chemi-
cally similar to an inhibitor in the training set,
and another representing the likelihood that a
non-inhibitor in the test set is most similar to
a non-inhibitor in the training set. To compute
similarities between training and test set com-
pounds and identify the nearest neighbors for
each test compound, we used a distance metric
appropriate to the type of features used in the
model: Tanimoto distance for ECFP features,
and Euclidean distance for MOE or Mordred
descriptors. Details of our modifications to the
published AVE debiasing algorithm are given in
the supplement. Note that in our implementa-
tion, the AVE debiasing split is applied twice,
first to select a held-out test set, and again to
choose compounds for the validation set. Be-
cause the validation set is used to select optimal
model parameters (as described below), we hy-
pothesized that models trained with the AVE
debiasing split would perform better against
external test compounds than models trained
with other splitting algorithms.
Model training
Neural network and random forest models were
trained and evaluated using a data-driven mod-
eling pipeline, AMPL, developed by our group
at the ATOM Consortium.21 Neural networks
consisted of one, two or three fully connected
hidden layers, with varying numbers of recti-
fied linear unit (ReLU) nodes per layer. Dur-
ing training and evaluation, 30% of nodes were
dropped out randomly to avoid overfitting.
Random forest models were trained with vary-
ing numbers of decision trees, maximum depth,
and maximum numbers of features used per
split. The underlying models were implemented
with the DeepChem and scikit-learn packages.
Both classification and regression models were
trained and tested.
As an additional strategy to avoid overfit-
ting neural network models, we implemented
an early stopping procedure as follows: Models
were evaluated after each training epoch, using
the validation set to compute the area under the
receiver operating characteristic curve (ROC
AUC) for classification, or the coefficient of de-
termination (R2) for regression models. After
training for a preset number of epochs (500), we
noted the epoch yielding the maximum valida-
tion score and used the corresponding network
weights as the parameters for the final model.
The early stopping scheme is illustrated in Fig-
ure 2. Note that, while the training set R2 score
continues to increase, the validation and test set
scores reach a peak and then gradually decline,
as the model becomes more overfitted to the
training set data.
To optimize neural network performance, we
ran hyperparameter searches for each splitting
method and feature type, varying the numbers
of hidden layers, number of nodes per layer,
and learning rate. We ran similar hyperparam-
eter searches for random forest models, vary-
ing the number of trees, maximum tree depth
and maximum features per split. Model pa-
rameters and performance metrics were stored
in a MongoDB database for subsequent analy-
sis; over 6,600 classification models and 8,900
regression models were evaluated.
Performance evaluation
Following standard machine learning practices,
we selected the best model parameters for each
choice of model type, feature set and splitting
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Figure 2: Illustration of early stopping proce-
dure for neural network training. The graph
shows the evolution of regression model per-
formance (R2) over the course of training for
the training (blue), validation (green) and test
sets (red). Neural network weights for the final
model are taken from the end of the training
epoch yielding the best R2 for the validation
set, indicated here by a vertical dashed line.
strategy based on validation set performance
metrics: ROC AUC for classification models
and R2 for regression models. We then eval-
uated a variety of performance metrics for the
best models against the held-out test set and
report these values here. In addition to the
ROC AUC, the metrics reported for classifi-
cation models include the following, defined in
terms of the counts of true positives (TP ), true
negatives (TN), false positives (FP ) and false
negatives (FN):
• Area under the precision vs recall curve
(PRC AUC).
• Precision or positive predictive value
(PPV):
TP
TP + FP
• Negative Predictive Value (NPV):
TN
TN + FN
• Recall or sensitivity:
TP
TP + FN
• Accuracy:
TP + TN
TP + TN + FP + FN
• Matthews correlation coefficient (MCC):
TP · TN − FP · FN√
(TP + FP )(TP + FN)(TN + FP )(TN + FN)
For regression models, we report the follow-
ing performance metrics, defined in terms of the
true pIC50 values yi, the predicted values yˆi for
each compound, and the mean true value y¯:
• Coefficient of determination (R2):
1−
∑n
i=1(yi − yˆi)2∑n
i=1(yi − y¯)2
• Mean absolute error (MAE):
1
n
n∑
i=1
|yi − yˆi|
• Root mean square error (RMSE):√√√√ 1
n
n∑
i=1
(yi − yˆi)2
Results and Discussion
Performance of BSEP classifica-
tion models
Figure 3 summarizes the performance, mea-
sured as the test set ROC AUC, of the best clas-
sification model for each combination of model
type (random forest or neural network), data
set splitting method, and type of chemical fea-
tures. Characteristics of the models and ROC
AUC scores for each dataset partition are shown
in Tables 1 and 2. More detailed tables of
model characteristics and performance metrics
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are given in Supplemental Tables S1 and S2.
The figure makes it clear that the splitting al-
gorithm has a marked effect on measured per-
formance. Generally speaking, the AVE bias
minimizing splitter provided the most stringent
performance assessment, with AUC scores av-
eraging about 0.1 units smaller than the corre-
sponding scores for random and scaffold splits.
Among the best models of a given type trained
with the same splitter, those using MOE de-
scriptor features almost always performed bet-
ter; the exceptions were the neural network
models trained with the AVE debiasing split-
ter, for which the highest ROC AUC score was
achieved with Mordred descriptors.
The best performing model overall was a
random forest with MOE descriptor features,
trained with a scaffold splitter; it contained
61 trees with maximum depth 9. It achieved
a test set ROC AUC of 0.936, 87% accu-
racy, precision 0.84, recall 0.89, negative predic-
tive value 0.89 and Matthews correlation coef-
ficient 0.74. These metrics significantly exceed
those reported for the best previously published
model.14
Reproducibility of model perfor-
mance results
Models trained with the same parameters can
yield different predictions and consequently dif-
ferent performance metrics, due to stochastic
elements of the data partitioning, featuriza-
tion and model training process. We assessed
the variation in test set ROC AUC metrics
across sets of 6 to 23 identically trained mod-
els for each combination of model type, splitter
and feature type, using the parameters for the
best performing models listed in tables 1 and 2
above. The results are shown in Figure 4 and
in Table 3. Generally, the random forest per-
formance metrics were stable when the mod-
els were retrained, except when the AVE bias
minimizing splitter was used. Neural networks
showed greater variations in performance, due
to the random dropouts used both at training
and at prediction time.
Comparison of results with single-
and dual-threshold classification
schemes
The best previously reported model of BSEP
inhibition14 used a dual-threshold classification
scheme that excluded weak BSEP inhibitors
from the training and test sets. We performed
an experiment to quantify the effect of such a
scheme on reported performance. Following the
same procedure as Montanari et al., we con-
structed a dual-threshold training and testing
data set from which compounds with IC50s be-
tween 10 and 50 µM were excluded; compounds
were classified as inhibitors if their IC50 was
< 10 and as non-inhibitors if IC50 was > 50µM.
We used this dataset to train and test 220 neu-
ral network models, 113 with MOE and 107
with Mordred descriptor features, with a va-
riety of hidden layer architectures. We trained
and tested the same number of models, with
equivalent feature sets and layer architectures,
against our standard single-threshold classifica-
tion dataset. For each split method, feature
type and model architecture, we computed the
change in test set ROC AUC scores between the
models trained on dual- and single-threshold
datasets.
Figure 5 shows the frequency distribution of
these differences. We see that using a dual-
threshold dataset increases the measured ROC
AUC in almost all (95%) of cases; in the most
extreme case, the AUC increased from 0.84 to
0.96. Table 4 shows the ROC AUC metrics for
the models that performed best on the dual-
threshold dataset for each split method and fea-
ture type, and corresponding models trained
and tested on the single-threshold dataset.
Models built using random splits tended to have
greater increases in assessed performance than
those trained with scaffold splits, averaging 0.06
for random vs 0.03 for scaffold splits. We
find therefore that dual-threshold classification
schemes lead to models with inflated perfor-
mance estimates. Since compounds with inter-
mediate IC50s for BSEP inhibition will be fre-
quently encountered in drug discovery projects,
such models can be expected to perform poorly
in realistic applications.
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Figure 3: Performance of best classification models for each model type, feature type, and data set
splitting method, computed as ROC AUC for test set predictions.
Figure 4: Variation of test set ROC AUC metrics across 10 identically trained classification models
for each model type, feature type, and data set splitting method. Bars show mean values with error
bars spanning ± 1 SD.
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Table 1: Hyperparameters and ROC AUC scores for best neural network classification models. Test
set ROC AUCs for best performing models within each splitter class are highlighted in yellow.
Splitter Features # Hidden layers Hidden layer sizes Training epochs
ROC AUC
Training
set
Validation
set
Test
set
External
set
AVE bias minimizing
ECFP 2 64,8 2 0.952 0.699 0.770 0.752
MOE 2 12,7 155 0.990 0.866 0.799 0.836
Mordred 2 15,5 10 0.926 0.834 0.849 0.856
Random
ECFP 3 14,12,7 13 0.959 0.913 0.846 0.773
MOE 3 15,6,3 74 0.967 0.911 0.882 0.883
Mordred 3 13,5,3 96 0.969 0.950 0.868 0.854
Scaffold
ECFP 2 16,11 4 0.918 0.883 0.833 0.771
MOE 3 32,16,4 128 0.969 0.905 0.907 0.816
Mordred 3 64,16,1 17 0.914 0.899 0.851 0.845
Table 2: Hyperparameters and ROC AUC scores for best random forest classification models. Test
set ROC AUCs for best performing models within each splitter class are highlighted in yellow; the
best overall ROC AUC is highlighted in orange.
Splitter Features # Trees Max depth Max features per split
ROC AUC
Training
set
Validation
set
Test
set
External
set
AVE bias minimizing
ECFP 35 9 32 0.996 0.689 0.714 0.735
MOE 46 5 32 0.989 0.829 0.823 0.887
Mordred 500 10 64 1.000 0.788 0.786 0.874
Random
ECFP 107 18 32 1.000 0.893 0.841 0.798
MOE 248 9 32 1.000 0.913 0.908 0.887
Mordred 141 71 32 1.000 0.917 0.879 0.862
Scaffold
ECFP 327 13 32 1.000 0.858 0.867 0.759
MOE 61 9 32 1.000 0.906 0.936 0.876
Mordred 572 18 32 1.000 0.854 0.894 0.872
Table 3: Ranges of test set ROC AUC scores across classification models retrained with best
parameters for each model type, feature type, and data set splitting method.
Model type Splitter Features Original test set ROC AUC
Test set ROC AUCs for retrained models
Mean Standard deviation
Neural n˚etwork
AVE bias minimizing
ECFP 0.770 0.767 0.022
MOE 0.799 0.815 0.013
Mordred 0.849 0.812 0.015
Random
ECFP 0.846 0.846 0.007
MOE 0.882 0.880 0.012
Mordred 0.868 0.857 0.027
Scaffold
ECFP 0.833 0.813 0.014
MOE 0.907 0.893 0.010
Mordred 0.851 0.822 0.027
Random f˚orest
AVE bias minimizing
ECFP 0.823 0.742 0.026
MOE 0.816 0.836 0.017
Mordred 0.791 0.796 0.027
Random
ECFP 0.849 0.858 0.004
MOE 0.900 0.906 0.002
Mordred 0.879 0.881 0.001
Scaffold
ECFP 0.882 0.846 0.013
MOE 0.925 0.906 0.007
Mordred 0.891 0.868 0.009
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Figure 5: Distribution of increases in measured test set performance for neural network models
trained and evaluated with dual-threshold classification datasets, compared to models of identical
design trained and tested with single-threshold classification datasets.
Table 4: Comparison of best performing models trained and tested with dual- vs single-threshold
datasets, for each splitting method and feature type.
Splitting method Feature type Hidden layers Layer sizes
Test set ROC AUC score
Single
threshold
Dual
thresh-
old
Random
MOE 1 8 0.871 0.936
Mordred 3 64,2,1 0.806 0.847
Scaffold
MOE 3 16,4,2 0.898 0.920
Mordred 2 8,4 0.889 0.907
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Evaluation against external test
set
For each combination of model type (neural
network or random forest), splitting method
and feature type, we selected our best perform-
ing classification model and used it to predict
BSEP inhibition for a set of 366 compounds
whose IC50s were measured by Warner et al.12
While the criterion used by Warner et al. to
label a compound as an inhibitor was that its
IC50 be less than 300 µM, we used a 50 µM
threshold instead to maximize consistency be-
tween their labels and ours, as described in
Methods. We computed the same performance
metrics for the predictions as for our internal
test set. The ROC AUC metrics for the exter-
nal test set predictions are plotted in Figure 6
and tabulated in Tables 1 and 2. In Figure 7, we
compare the performance metrics for the pre-
dictions on the internal and external test sets.
Models based on MOE and Mordred descrip-
tors generally performed well on the external
dataset, in some cases with ROC AUCs ex-
ceeding those obtained on the internal test set.
Since the external test compounds were selected
to be chemically dissimilar from all compounds
in our internal training and testing set, our re-
sults suggest that our classification models gen-
eralize well to new chemistry.
The type of split used to train a model did
not greatly affect the absolute performance on
the external dataset. However, it was notable
that almost all of the best models trained with
the AVE debiasing splitter performed better on
the external dataset than on the internal test
set. This was not true for models trained with
the other splitters. The model with best overall
performance on the external set was a MOE
descriptor based random forest trained with an
AVE debiasing split. This result provides some
support for the hypothesis that removing AVE
bias when partitioning datasets favors models
that generalize beyond the training data.
Performance of open-source BSEP
classification models
To provide classification models for use by the
community, we trained a series of neural net-
work models on a class-balanced dataset based
on publicly available data for 660 compounds,
with open-source Mordred descriptors as fea-
tures. The input dataset was split into training,
validation and test sets in the same way as the
public-proprietary combined dataset, with 70%,
15% and 15% of the compounds respectively,
using either a random or a scaffold-based split-
ter. For each splitter, 124 models with different
network architectures were trained. The best
performing model was selected for each splitter
based on the validation set ROC AUC score.
The best models were then evaluated against
the internal test set, and also on an external
test set containing all GSK compounds from the
public-proprietary combined dataset, filtered to
exclude compounds structurally similar to any
training, validation or test set compound.
Table 5 shows the ROC AUC scores for the
best models trained with each splitter type;
additional performance metrics are shown in
Supplemental Table S3. Generally speaking,
the models trained with a random split pro-
duced higher ROC AUC scores than the scaffold
split models when evaluated against the inter-
nal held-out test set. However, the best scaffold
split model scored slightly better than the ran-
dom split when assessed on the external test set.
The relative generalization powers of the ran-
dom and scaffold split models, as measured by
performance on the external test set, depended
on the choice of performance metric. While
the two models had similar values for the ROC
AUC, PRC AUC, accuracy and MCC metrics,
the scaffold split model had notably better pre-
cision (0.83 vs 0.78), worse recall (0.75 vs 0.88)
and worse NPV (0.62 vs 0.73) compared to the
random split model.
Comparing performance of models trained
with public vs proprietary data is problematic,
given the lack of a common test set and the
limited range of model and feature types tested
with public data. Nevertheless, we observe
that, by most metrics, our public-data mod-
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Figure 6: Performance of best classification models on external test set for each model type, feature
type, and data set splitting method, computed as ROC AUC for external test set predictions.
Model types are random forests (RF) and neural networks (NN).
Figure 7: Comparison of classification model performance on external vs internal test sets. Markers
are color coded by split type, shape coded by feature type, and sized by model type. The dashed
line represents identical performance on the two datasets.
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Table 5: Performance (area under ROC curve) of best classification models trained against publicly
available data.
Splitter Features # Hidden layers Hidden layer sizes Training epochs
ROC AUC
Training
set
Validation
set
Test set External
set
Random Mordred 3 16,9,5 264 0.995 0.901 0.912 0.802
Scaffold Mordred 3 16,12,3 359 1 0.875 0.742 0.812
els perform almost as well as our proprietary-
data models against their respective external
test sets. We also noted that our models per-
formed better than the best previously pub-
lished model on their internal test sets. Our
best public-data models for each split and the
code and data used to generate them are avail-
able as supplementary data, for use with our
open source AMPL modeling pipeline.
Performance of BSEP regression
(pIC50) models
Figure 8 summarizes the performance, mea-
sured by test set R2 scores, of the best re-
gression models for each combination of model
type, split method, and feature type. Charac-
teristics of the models and R2 scores for each
subset are shown in Tables 6 and 7, while ad-
ditional performance metrics are documented
in Supplemental Tables S4 and S5. As with
classification models, the AVE debiasing split-
ter resulted in lower reported performance met-
rics than random or scaffold splitting, and mod-
els featurized using chemical descriptors usually
performed much better than models based on
ECFP4 fingerprints. In fact, the “best” neural
network model (in terms of validation set R2)
trained with a scaffold split and ECFP4 finger-
prints yielded a negative R2 value on the test
set, indicating that the residual variance of its
predictions was greater than the sample vari-
ance of the data.
In 4 out of 6 cases, models using MOE de-
scriptors outperformed Mordred-based models
of the same type trained with the same splitter;
however, the models with the best overall re-
ported metrics were based on Mordred descrip-
tors, with the top neural network model slightly
outperforming its random forest counterpart. It
had a test set R2 of 0.557, mean absolute er-
ror (MAE) 0.37, and RMS error 0.577. Since
the predicted pIC50 values are log space mea-
surements, the MAE corresponds to a 100.37 or
2.3-fold error in predicted IC50s. This result is
comparable to the observed variation between
experimental replicates in our laboratory, sug-
gesting that further increases in accuracy may
be difficult to achieve. We note however that,
since this model was trained using a random
split, its performance metrics may be inflated
due to similarities between some test and train-
ing compounds.
In general, regression models for dose-
response assays are challenging to fit, due to
the limited range of compound concentrations
tested. Compounds that don’t produce at least
50% inhibition at the maximum concentration
Cmax are reported as having IC50 > Cmax;
the corresponding pIC50 values are thus left-
censored at − log10Cmax. It is also possible
for dose-response datasets to be right-censored;
for example, Warner et al. tested compounds
at a minimum concentration of 10 µM, so the
maximum pIC50 reported in their dataset is 5.
Additional complications result when, as in our
combined dataset, the data contain a mixture
of values censored at different thresholds. The
situation is illustrated in Figure 9, which shows
the predicted pIC50 values for our best per-
forming model plotted against the actual mea-
sured values for the test dataset compounds.
In our combined dataset, the measured IC50
values were typically censored at either 133
µM (from the Morgan et al. dataset) or 200
µM (from the GSK subset). The two vertical
strings of points at the lower left corner of the
plot represent the spread of predictions for the
compounds with censored measurements.
Typically, researchers follow one of two ap-
15
Figure 8: Performance of best regression models for each model type, feature type, and data set
splitting method, measured as R2 for test set predictions.
Table 6: Model hyperparameters and R2 scores of best neural network regression models. Test set
R2 values for best performing models within each splitter class are highlighted in yellow; the best
overall R2 is highlighted in orange.
Splitter Features # hidden layers Hidden layer sizes Training epochs
R2
Training
set
Validation
set
Test set
AVE bias minimizing
ECFP 1 16 16 0.620 0.209 0.214
MOE 3 128,32,16 125 0.841 0.498 0.368
Mordred 2 64,4 202 0.813 0.503 0.264
Random
ECFP 1 16 14 0.577 0.351 0.345
MOE 2 32,15 349 0.891 0.583 0.435
Mordred 2 64,12 478 0.927 0.601 0.557
Scaffold
ECFP 3 16,15,13 229 0.814 0.360 -0.045
MOE 1 128 133 0.673 0.554 0.521
Mordred 2 64,14 24 0.608 0.506 0.426
Table 7: Model hyperparameters and R2 scores of best random forest regression models.
Splitter Features # Trees Max depth Max features per split
R2
Training
set
Validation
set
Test set
AVE bias minimizing
ECFP 81 18 32 0.871 0.233 0.184
MOE 61 18 32 0.945 0.441 0.405
Mordred 11 26 32 0.903 0.396 0.160
Random
ECFP 46 36 32 0.906 0.392 0.324
MOE 61 100 32 0.943 0.618 0.397
Mordred 107 13 32 0.922 0.559 0.557
Scaffold
ECFP 20 100 32 0.890 0.339 0.195
MOE 46 13 32 0.934 0.529 0.504
Mordred 26 13 32 0.918 0.459 0.405
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proaches to fit regression models to pIC50 data:
either omit the censored data points from the
training and testing sets, or add an arbitrary
negative offset to the censored pIC50 values.
For the sake of interpretability, we did not use
the latter approach here; and in our experience,
removing censored data points from the train-
ing set yields less predictive regression models.
A more robust approach to quantitatively pre-
dict BSEP inhibition would use a hybrid model,
combining a classifier to predict whether the
pIC50 was above or below the censoring thresh-
old, together with a regression model trained
only on uncensored data that would be applied
only to compounds predicted to have pIC50s
above the threshold. Alternatively, one could
fit a Tobit model,26 which predicts the mean
and variance of a Gaussian distribution under-
lying the observed censored pIC50 values for
each compound. Both of these approaches are
being actively investigated by our group.
Conclusions
In this work, we have presented our results
from using an automated data-driven model-
ing pipeline (AMPL) to train and evaluate over
15,500 classification and regression models of
BSEP inhibition, based on a combined propri-
etary and public dataset containing IC50 data
for 1,149 compounds. By using the hyperpa-
rameter search capability of AMPL, we were
able to test a wide variety of combinations of
model types, dataset splitting strategies, chem-
ical featurization methods, and model param-
eters. When evaluated against our internal
held-out test dataset, our best model signif-
icantly outperformed the best previously re-
ported model across all standard metrics for
classification models. Its superior performance
is especially remarkable, given our demon-
stration that the dual-threshold classification
scheme used to train and test the competing
model leads to inflated performance estimates.
While our best model and the one reported by
Montanari et al. both used a random forest
algorithm with MOE descriptors as features,
it appears that the random forest implementa-
tion used by AMPL (based on the scikit-learn
Python package) allows variation of a wider
range of model parameters than the Weka soft-
ware used by Montanari et al. In addition, the
hyperparameter search tools in AMPL allowed
us to test many combinations of parameters to
find an optimal set.
For each combination of model type, splitter
and feature type, we tested the best performing
classification model against a publicly available
external dataset to assess its power to generalize
to novel chemistry. We found that models based
on MOE descriptors generally performed best
when evaluated against both our internal test
set and the external dataset; however, models
using Mordred descriptors performed almost as
well, and outperformed MOE descriptors in a
few cases.
Our study found much variation in assessed
performance between models trained using dif-
ferent dataset splitting strategies, with the AVE
debiasing splitter providing more stringent tests
of model performance on our internal test set.
When we compared performance on the exter-
nal dataset to the internal test set, most mod-
els trained with the AVE splitter scored better
on the external set, despite the fact that the
external set was filtered to exclude compounds
with structural similarity to the training data.
While this result suggests that AVE debiasing
may help produce models that generalize bet-
ter, we note that the model that scored best
on the external set (which was trained with
an AVE split) only slightly outperformed an-
other model that used a random split. We plan
in future work to further investigate the fac-
tors affecting generalization performance, using
a wider variety of datasets.
To our knowledge, our study is the first to
report results from fitting regression models
to predict pIC50 values for BSEP inhibition.
We found that our best model achieved a rea-
sonable coefficient of determination (R2), the
most commonly used metric for regression mod-
els. More importantly for practical purposes,
its mean absolute error (MAE) corresponds to
a 2.3-fold variation in predicted IC50 values.
This is on the same scale as the observed vari-
ation across experimental replicate IC50 mea-
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Figure 9: Predicted vs actual test set pIC50 values for the best overall regression model. Com-
pounds whose actual pIC50 values were left-censored are represented by triangles. The dashed line
represents the identity relation.
surements. We are excited by this result, as it
means that the model can be used to predict in-
put values for simulations of drug-induced liver
injury (e.g., DILI-sym), as well as in compu-
tational pipelines for in silico drug discovery.
We look forward to the availability of large
datasets measuring inhibition of other bile salt
transporters, such as NTCP, MRP3 and MRP4;
this will make possible the construction of accu-
rate models for these additional factors which
are important predictors of cholestatic drug-
induced liver injury.
In order to make models of BSEP inhibi-
tion widely available and encourage develop-
ment of improved models, we trained a series
of models on publicly available data and eval-
uated their generalization power on a propri-
etary compound set. The best performing mod-
els, along with code and data used to gener-
ate them, are released as supplementary data
with this article, to be used with the open-
source AMPL pipeline software. We hope that
other researchers will use the AMPL platform
to develop even better models, by training a
wider variety of model architectures against
larger, more diverse datasets, and contribute
their models to the community.
Disclaimer
This document was prepared as an account of
work sponsored by an agency of the United
States government. Neither the United States
government nor Lawrence Livermore National
Security, LLC, nor any of their employees makes
any warranty, expressed or implied, or assumes
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curacy, completeness, or usefulness of any in-
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ernment or Lawrence Livermore National Secu-
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Supplemental Information
Models, Software and Training
Data
Models trained with publicly available data,
along with the data and code used to
train and test them, are available at the
AMPL GitHub repository: https://github.
com/ATOMconsortium/AMPL, in subdirectory
atomsci/ddm/examples/BSEP. Instructions for
running the models are in the file README.md
in that directory.
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Maximum Likelihood Mean Es-
timation for Partially Censored
Data
Estimates of IC50 drug concentrations for a
particular biological activity, such as BSEP in-
hibition, are restricted by the range of con-
centrations over which activities are measured,
[Cmin, Cmax]. If the target activity at Cmax is
not reduced by at least 50%, the IC50 is typi-
cally reported as > Cmax and the corresponding
pIC50 as < − log10Cmax; that is, the pIC50 ob-
servations are left-censored. Likewise, observa-
tions may be right-censored if > 50% inhibition
occurs at all concentrations tested.
In our BSEP inhibition training and testing
dataset, we had replicate pIC50 measurements
reported as xi, i = 1 . . . n, for most compounds;
these were combined to produce a single pIC50
value for each compound. In many cases, some
or all of the replicate measurements were cen-
sored. We treated the replicates as samples
from an underlying Gaussian distribution with
mean µ and standard deviation σ. We esti-
mated µ as follows for the four possible cases:
• All replicates left-censored:
µˆ = min
i=1...n
xi
• All replicates right-censored:
µˆ = max
i=1...n
xi
• All replicates uncensored:
µˆ =
1
n
n∑
i=1
xi
• Some replicates censored, some uncen-
sored:
µˆ = argmaxµL(µ, σ;x)
where L(µ, σ;x) is the log likelihood func-
tion defined as follows:
L(µ, σ;x) =
∑
i∈U
log φ
(
xi − µ
σ
)
+
∑
i∈L
log Φ
(
xi − µ
σ
)
+
∑
i∈R
log
[
1− Φ
(
xi − µ
σ
)]
In the above, U,L and R are respectively
the sets of replicate indices for uncensored,
left- and right-censored measurements; φ is
the probability density function for the stan-
dard Gaussian distribution; and Φ is the cu-
mulative distribution function for the standard
Gaussian distribution. We estimated a com-
mon standard deviation parameter σ for all
compounds by computing the RMS deviation
of all uncensored replicate measurements from
their compound-specific means, across com-
pounds with at least two uncensored repli-
cates. The maximum likelihood estimate was
obtained using Brent’s algorithm, as imple-
mented in package scipy.optimize function
minimize scalar.
Modifications to AVE Debiasing
Algorithm
To partition training, validation and test
datasets, we implemented a modified version of
the asymmetric validation embedding (AVE)
bias minimization algorithm presented by Wal-
lach et al.17 The original algorithm seeks to
minimize the AVE bias, defined as follows: Let
T and V be proposed training and validation
sets of compounds, and let Ta, Ti, Va and Vi be
the sets of “active” and “inactive” compounds
within the training and validation sets. For our
model, actives correspond to BSEP inhibitors
and inactives to non-inhibitors. Define the
“nearest neighbor function”:
S(V, T, d) =
1
|V |
∑
v∈V
I [Dnn(v, T ) < d]
where Dnn(v, T ) is the Tanimoto distance of
compound v from its nearest neighbor in T ,
and I is the indicator function. Note that,
when the sets T and V are fixed, S(V, T, d) is
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the cumulative empirical distribution function
of Dnn(v, T ). Next, fix a set of distance thresh-
olds D; Wallach et al. use D = {0, 0.01, . . . , 1}
for Tanimoto distance. Then, define the aver-
age CDF over this set of distances:
H(V, T ) =
1
|D|
∑
d∈D
S(V, T, d)
Finally, the AVE bias is defined as:
B(Va, Vi, Ta, Ti) = [H(Va, Ta)−H(Va, Ti)]
+ [H(Vi, Ti)−H(Vi, Ta)]
The first bracketed term is similar to the
MUV bias defined by Rohrer et al.;16 it rep-
resents the tendency for validation set active
compounds to cluster with training set actives.
The second bracketed term measures the ten-
dency for validation set inactives to cluster with
training set inactives. Either of these terms
can be negative; therefore a training/validation
split with a negative contribution from the in-
active term and positive contribution from the
active term can appear to have low bias. We
viewed this as a defect in the AVE debias-
ing algorithm, since it favors classification al-
gorithms that memorize the active compounds
in the training data. In our implementation, we
used a modified version of the AVE bias that en-
forces positive contributions for both the active
and inactive compounds:
B′(Va, Vi, Ta, Ti) = |H(Va, Ta)−H(Va, Ti)|
+ |H(Vi, Ti)−H(Vi, Ta)|
Our second modification to the AVE debias-
ing algorithm was to support chemical descrip-
tor features as an alternative to the fingerprint
bit vectors supported by the original algorithm.
For models using descriptors as features, we
use Euclidean distance between feature vectors
to compute nearest-neighbor distances. Un-
like Tanimoto distances, these distances are not
bounded in the range [0,1], so an alternative set
of distances D must be used to compute the av-
erage CDF H(V, T ). We chose a similar set to
the one used by Rohrer et al. to compute the
MUV bias: a set of 100 evenly spaced distances
from 0 to 3 · median(Dnn), where the median
was computed over the distances from all com-
pounds to their nearest neighbors in the unpar-
titioned dataset.
In most other respects, our version of the AVE
debiasing algorithm follows the implementation
provided by Wallach et al.; it generates a set of
random 2-way splits, then uses a genetic algo-
rithm to combine and mutate the splits iter-
atively until the computed AVE bias falls be-
low some threshold. To generate the 3-way
training/validation/test splits we use for model
building and evaluation, we perform an initial
2-way split to select the held-out test set, fol-
lowed by a second split on the remaining com-
pounds to separate the training and validation
sets. The final training and test sets may have
a small residual AVE bias due to the removal of
the validation set compounds, but in our expe-
rience it is not large enough to be of concern.
Supplemental Tables
Splitter Features # Hidden layers Hidden layer sizes Training epochs
ROC AUC PRC AUC Accuracy Precision Recall NPV MCC
Training
set
Validation
set
Test
set
External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
AVE bias minimizing
ECFP 2 64,8 2 0.952 0.699 0.770 0.752 0.945 0.659 0.716 0.627 0.866 0.661 0.717 0.678 0.929 0.705 0.745 0.867 0.752 0.419 0.528 0.101 0.831 0.645 0.704 0.670 0.733 0.310 0.418 0.223
MOE 2 12,7 155 0.990 0.866 0.799 0.836 0.989 0.828 0.742 0.707 0.958 0.787 0.737 0.767 0.991 0.790 0.784 0.734 0.914 0.690 0.548 0.535 0.936 0.784 0.716 0.779 0.917 0.562 0.464 0.469
Mordred 2 15,5 10 0.926 0.834 0.849 0.856 0.900 0.782 0.765 0.721 0.847 0.755 0.794 0.801 0.803 0.678 0.714 0.759 0.865 0.831 0.878 0.636 0.887 0.842 0.886 0.818 0.694 0.523 0.604 0.551
Random
ECFP 3 14,12,7 13 0.959 0.913 0.846 0.773 0.952 0.893 0.847 0.668 0.876 0.831 0.780 0.694 0.894 0.852 0.781 0.707 0.814 0.722 0.722 0.225 0.863 0.820 0.780 0.692 0.748 0.652 0.556 0.264
MOE 3 15,6,3 74 0.967 0.911 0.882 0.883 0.959 0.853 0.833 0.756 0.925 0.860 0.827 0.764 0.933 0.911 0.838 0.765 0.897 0.729 0.750 0.481 0.919 0.836 0.819 0.764 0.849 0.712 0.647 0.460
Mordred 3 13,5,3 96 0.969 0.950 0.868 0.854 0.958 0.932 0.868 0.770 0.949 0.849 0.780 0.798 0.970 0.883 0.824 0.802 0.912 0.736 0.683 0.566 0.935 0.830 0.752 0.796 0.897 0.689 0.563 0.542
Scaffold
ECFP 2 16,11 4 0.918 0.883 0.833 0.771 0.870 0.906 0.870 0.659 0.770 0.593 0.584 0.680 0.932 0.966 1.000 1.000 0.441 0.289 0.242 0.093 0.733 0.517 0.520 0.669 0.529 0.365 0.355 0.250
MOE 3 32,16,4 128 0.969 0.905 0.907 0.816 0.969 0.916 0.899 0.689 0.960 0.814 0.815 0.767 0.990 0.875 0.819 0.700 0.910 0.786 0.800 0.597 0.943 0.750 0.811 0.796 0.918 0.631 0.630 0.476
Mordred 3 64,16,1 17 0.914 0.899 0.851 0.845 0.803 0.913 0.827 0.692 0.866 0.791 0.740 0.790 0.815 0.918 0.798 0.728 0.847 0.691 0.705 0.643 0.900 0.697 0.685 0.817 0.720 0.613 0.485 0.529
Table S1. Full performance metrics for best neural network classification models.
Splitter Features # Trees Max depth Max features per split
ROC AUC PRC AUC Accuracy Precision Recall NPV MCC
Training
set
Validation
set
Test
set
External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
AVE bias minimizing
ECFP 35 9 32 0.996 0.689 0.714 0.735 0.995 0.650 0.636 0.616 0.946 0.636 0.663 0.710 0.997 0.652 0.682 0.709 0.879 0.405 0.417 0.302 0.913 0.630 0.656 0.711 0.893 0.255 0.301 0.314
MOE 46 5 32 0.989 0.829 0.823 0.887 0.986 0.783 0.785 0.817 0.952 0.750 0.754 0.808 0.933 0.688 0.722 0.804 0.960 0.775 0.712 0.605 0.968 0.810 0.779 0.810 0.903 0.501 0.500 0.567
Mordred 500 10 64 1.000 0.788 0.786 0.874 1.000 0.746 0.756 0.780 0.999 0.706 0.700 0.781 0.997 0.642 0.662 0.753 1.000 0.732 0.635 0.566 1.000 0.768 0.727 0.792 0.997 0.414 0.387 0.503
Random
ECFP 107 18 32 1.000 0.893 0.841 0.798 1.000 0.855 0.835 0.680 0.990 0.820 0.763 0.732 1.000 0.815 0.797 0.746 0.977 0.736 0.646 0.364 0.983 0.822 0.743 0.729 0.980 0.627 0.523 0.376
MOE 248 9 32 1.000 0.913 0.908 0.887 1.000 0.866 0.896 0.810 0.994 0.831 0.815 0.795 0.986 0.825 0.806 0.770 1.000 0.743 0.763 0.597 1.000 0.835 0.822 0.804 0.988 0.648 0.623 0.535
Mordred 141 71 32 1.000 0.917 0.879 0.862 1.000 0.904 0.869 0.763 0.998 0.855 0.815 0.776 0.997 0.841 0.821 0.764 0.997 0.806 0.780 0.527 0.998 0.864 0.811 0.780 0.995 0.700 0.629 0.488
Scaffold
ECFP 327 13 32 1.000 0.858 0.867 0.759 0.999 0.885 0.901 0.646 0.966 0.663 0.688 0.705 1.000 0.953 0.936 0.784 0.914 0.423 0.463 0.225 0.948 0.566 0.595 0.696 0.931 0.454 0.475 0.303
MOE 61 9 32 1.000 0.906 0.936 0.876 1.000 0.926 0.935 0.786 0.990 0.820 0.867 0.792 0.979 0.825 0.844 0.743 0.997 0.867 0.894 0.628 0.998 0.812 0.892 0.813 0.979 0.630 0.736 0.532
Mordred 572 18 32 1.000 0.854 0.894 0.872 1.000 0.869 0.902 0.763 0.998 0.779 0.798 0.762 1.000 0.855 0.849 0.739 0.994 0.732 0.768 0.504 0.996 0.708 0.747 0.770 0.995 0.568 0.599 0.455
Table S2. Full performance metrics for best random forest classification models.
Splitter Features # Hidden layers Hidden layer sizes Training epochs
ROC AUC PRC AUC Accuracy Precision Recall NPV MCC
Training
set
Validation
set
Test
set
External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Training
set
Validation
set
Test set External
set
Random Mordred 3 16,9,5 264 0.995 0.901 0.912 0.802 0.992 0.884 0.86 0.849 0.976 0.8 0.859 0.767 0.96 0.763 0.81 0.781 0.991 0.725 0.85 0.883 0.992 0.823 0.895 0.732 0.953 0.58 0.709 0.478
Scaffold Mordred 3 16,12,3 359 1 0.875 0.742 0.812 1 0.866 0.648 0.869 0.993 0.75 0.717 0.743 1 0.769 0.689 0.832 0.985 0.652 0.689 0.75 0.988 0.738 0.741 0.623 0.987 0.496 0.43 0.468
Table S3. Full performance metrics for best open data based classification models.
Splitter Features # hidden layers Hidden layer sizes Training epochs
R2 Mean absolute error RMS error
Training
set
Validation
set
Test set Training
set
Validation
set
Test set Training
set
Validation
set
Test set
AVE bias minimizing
ECFP 1 16 16 0.620 0.209 0.214 0.338 0.489 0.492 0.487 0.618 0.600
MOE 3 128,32,16 125 0.841 0.498 0.368 0.208 0.342 0.346 0.317 0.507 0.521
Mordred 2 64,4 202 0.813 0.503 0.264 0.258 0.406 0.437 0.343 0.523 0.584
Random
ECFP 1 16 14 0.577 0.351 0.345 0.360 0.472 0.466 0.501 0.618 0.605
MOE 2 32,15 349 0.891 0.583 0.435 0.180 0.327 0.343 0.259 0.487 0.529
Mordred 2 64,12 478 0.927 0.601 0.557 0.129 0.296 0.373 0.201 0.482 0.577
Scaffold
ECFP 3 16,15,13 229 0.814 0.360 -0.045 0.263 0.525 0.641 0.308 0.687 0.849
MOE 1 128 133 0.673 0.554 0.521 0.260 0.426 0.422 0.405 0.598 0.572
Mordred 2 64,14 24 0.608 0.506 0.426 0.352 0.489 0.514 0.447 0.604 0.630
Table S4. Full performance metrics for best neural network regression models.
Splitter Features # Trees Max depth Max features per split
R2 Mean absolute error RMS error
Training
set
Validation
set
Test set Training
set
Validation
set
Test set Training
set
Validation
set
Test set
AVE bias minimizing
ECFP 81 18 32 0.871 0.233 0.184 0.225 0.476 0.488 0.284 0.609 0.612
MOE 61 18 32 0.945 0.441 0.405 0.128 0.379 0.365 0.187 0.535 0.506
Mordred 11 26 32 0.903 0.396 0.160 0.157 0.427 0.464 0.246 0.576 0.624
Random
ECFP 46 36 32 0.906 0.392 0.324 0.168 0.444 0.464 0.236 0.598 0.615
MOE 61 100 32 0.943 0.618 0.397 0.128 0.322 0.376 0.186 0.465 0.546
Mordred 107 13 32 0.922 0.559 0.557 0.151 0.355 0.429 0.208 0.507 0.577
Scaffold
ECFP 20 100 32 0.890 0.339 0.195 0.160 0.507 0.558 0.237 0.698 0.745
MOE 46 13 32 0.934 0.529 0.504 0.125 0.431 0.420 0.181 0.615 0.582
Mordred 26 13 32 0.918 0.459 0.405 0.141 0.472 0.469 0.205 0.632 0.641
Table S5. Full performance metrics for best random forest regression models.
